Cancer Fighters Thrive
®
10109 E. 79th Street
Tulsa, OK 74133
Important safety information
SANCUSO
®
(Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic
chemotherapy regimens of up to 5 consecutive days duration.
4
SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the
components of the patch.
4
Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition.
4
Mild application site reactions
have occurred; remove the patch if severe reaction or a generalized skin reaction occurs.
4
Patients should avoid direct exposure of application site to natural or
artifi cial sunlight by covering with clothing while wearing the patch and for 10 days after removing it.
4
The most common adverse reaction in patients receiving
SANCUSO is constipation (5.4%).
4
SANCUSO contains granisetron.
4
Healthcare professionals should avoid prescribing any additional products that contain
granisetron. No clinically relevant drug interactions have been reported in clinical studies with SANCUSO.
4
Keeps them covered
ONLY
References:
1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. V.1.2012. http://www.nccn.org/
professionals/physician_gls/pdf/antiemesis.pdf. Accessed December 13, 2011. 2. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American
Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2011;29(31):4189-4198. 3. Boccia RV, Gordan LN, Clark G, Howell
JD, Grunberg SM; on behalf of the Sancuso Study Group. Effi cacy and tolerability of transdermal granisetron for the control of chemotherapy-
induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III
study. Support Care Cancer. 2011;19(10):1609-1617. 4. SANCUSO [package insert]. Bridgewater, NJ: ProStrakan, Inc; 2011.
SANCUSO is a registered trademark of ProStrakan, Inc.
©2012 ProStrakan, Inc.
All rights reserved. Printed in U.S.A. SAN-2012-006 February 2012
www.prostrakan-usa.com
www.sancuso.com
Please see brief summary of
Prescribing Information on adjacent page.
When preparing for chemotherapy, be
For nausea and vomiting
One patch.
One application.
5 days of coverage.
3
Visit www.sancuso.com to learn
more and to download a money-
saving co-pay card.
SANCUSO
®
(Granisetron Transdermal System) :
A recommendation from
leading treatment guidelines
1,2
&
armed
&
ready
&
Please refer to the sunlight warning in
the important safety information below.